Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

60 Degrees Pharmaceuticals (SXTP) EBIT Margin (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed EBIT Margin for 4 consecutive years, with 531.42% as the latest value for Q3 2025.

  • On a quarterly basis, EBIT Margin rose 103458.0% to 531.42% in Q3 2025 year-over-year; TTM through Sep 2025 was 14.63%, a 195597.0% increase, with the full-year FY2024 number at 274.97%, up 175781.0% from a year prior.
  • EBIT Margin was 531.42% for Q3 2025 at 60 Degrees Pharmaceuticals, up from 1590.01% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 2474.5% in Q4 2024 to a low of 5536.13% in Q1 2023.
  • A 4-year average of 1279.17% and a median of 1323.65% in 2023 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: plummeted -334899bps in 2023, then surged 426576bps in 2024.
  • 60 Degrees Pharmaceuticals' EBIT Margin stood at 1841.87% in 2022, then plummeted by -182bps to 1507.12% in 2023, then surged by 264bps to 2474.5% in 2024, then plummeted by -121bps to 531.42% in 2025.
  • Per Business Quant, the three most recent readings for SXTP's EBIT Margin are 531.42% (Q3 2025), 1590.01% (Q2 2025), and 1168.36% (Q1 2025).